Minerva Neuroscience raises $96M in initial stock offering

Minerva Neuroscience, a small biotech that moved from New Jersey to Cambridge last year to develop drugs for schizophrenia and other diseases of the central nervous system, has raised $69 million in an initial public offering...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.